Clinical significance and risk factors of postembolization fever in patients with hepatocellular carcinoma

Table 2 Multivariate and univariate analysis for postembolization fever, 20-mo mortality, and tumor progression-free survival

Variables	HR	95%CI	P-value
Multivariate analysis1
ALT value after TACE	1.002	1.00-1.005	< 0.05
Lipiodol dose (< 7 mL)	0.539	0.329-0.881	< 0.05
Univariate analysis2
Poor BS control	2.673	1.77-4.034	< 0.01
Portal vein thrombosis	3.048	1.536-6.06	< 0.01
Poor CT response	2.638	1.785-3.891	< 0.01
Initial AST	1.006	1.001-1.011	< 0.05
Initial CRP	1.348	1.011-1.796	< 0.05
Tumor size	1.31	1.198-1.433	< 0.01
TNM	1.555	1.26-1.92	< 0.01
Lipiodol dose	1.12	1.058-1.185	< 0.01
Multivariate analysis3
Tumor size	1.252	1.108-1.414	< 0.01
Poor BS control	2.442	1.310-4.55	< 0.01
Portal vein thrombosis	3.344	1.021-10.98	< 0.05
Cox regression analysis4
Poor CT response after TACE	0.302	0.192-0.765	< 0.0
Lipiodol dose (≥ 7 mL)	0.494	0.279-0.874	< 0.05

¹Predictors for postembolization fever;

²Risk factors for 20-mo mortality;

³Predictors for 20-mo mortality;

⁴Predictors for tumor progression-free survival. HR: Hazard ratio; CRP: C-reactive protein; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; TNM: Tumor, node, metastases; TACE: Transcatheter arterial chemoembolization; BS: Base of support.